奈达铂联合长春瑞滨治疗65例晚期恶性肿瘤近期疗效观察  

Clinical observation of nedaplatin combined with vinorelbine in treating 65 cases of metastatic carcinoma

作　　者：蔡君[1] 李爽[1] 叶青青[1] 李晶晶[1] 柯庆华[1] 蒋代文[1] 杨继元[1] 

机构地区：[1]长江大学附属第一人民医院肿瘤科,湖北荆州434000

出　　处：《现代肿瘤医学》2010年第6期1219-1220,共2页Journal of Modern Oncology

摘　　要：目的:观察奈达铂与长春瑞滨联合化疗治疗晚期恶性肿瘤的临床疗效及不良反应。方法:65例转移癌患者,均采用奈达铂80mg/m2,第1天,长春瑞滨25mg/m2静脉滴注,第1、8天。每21天为1个周期,治疗4-6周期。结果:全组总有效率50.77%。转移性鳞癌有效率64.7%,转移性腺癌有效率为35.5%,两者疗效比较有显著性差异,P<0.05。主要不良反应为骨髓抑制,其他不良反应较轻。结论:奈达铂联合长春瑞滨化疗治疗转移性癌疗效好,副反应较轻,尤其适用于转移性鳞癌。Objective：To evaluate the efficacy and toxicity of nedaplatin combined with vinorelbine in treating metastatic carcinoma. Methods：Sixty five patients with metastatic carcinoma were treated with nedaplatin 80mg/m2 on days 1 and vinorelbine 25mg/m2 on day 1 and 8 delivered by venous injection for 4 - 6 cycles. Results ： Gross efficien- cy rate was 50.77 %. Metastatic squamous cell carcinoma efficiency rate was 64.7%, metastatic adenocarcinoma effi- ciency rate was 35.5%. The difference was significant （P 〈 0.05 ）. The main side effects were marrow suppression other side effects were slight. Conclusion：Nedaplatin combined with vinorelbine in treating metastatic carcinoma had better effective and less toxic effects, especially in treating metastatic squamous cell carcinoma.

关 键 词：奈达铂 化学治疗 长春瑞滨 

分 类 号：R730.3[医药卫生—肿瘤]